Apixaban Compared With Low Molecular Weight Heparins For Prophylaxis In The Patients At Risk Of Venous Thromboembolism: A Systematic Review And Meta-Analysis

Abstract

of stroke and SEE associated with edoxaban and warfarin users. ReSultS: Within NVAF adult patients (N = 1,012,245), we identified 744 qualified edoxaban users and 549 propensity score matched warfarin users between Jan. 2015 and Dec. 2017. Compared to warfarin, edoxaban is associated with similar risks in stroke (hazard ratio [HR] 0.89, 95% CI 0.58-1.39, p = 0.605), and with lower risks in systemic embolic events (hazard ratio [HR] 0.58, 95% CI 0.37-0.90, p = 0.014). ConCluSionS: The edoxaban is non-inferior in prevention of stroke but reduces the risk of embolism in comparison to warfarin in our studies using EHR data.